Trial Profile
A Real World Experience of Using First-Line Sunitinib or Pazopanibin in Canadian Patients With Metastatic Renal Cell Carcinoma (mRCC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Nov 2016
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 30 Nov 2016 New trial record
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress.